相关临床试验
8
5 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2014
进行中（未招募）
1
12.5%
已完成
2
25.0%
Enrolling By Invitation
1
12.5%
尚未招募
3
37.5%
招募中
1
12.5%
暂无批准数据
- Updated Phase 2 data on LUM-201 demonstrate sustained growth over 24 months in children with moderate Pediatric Growth Hormone Deficiency (PGHD). - The study showed a significant increase in Annualized Height Velocity (AHV) at six months, which was maintained through 24 months of treatment. - Data also revealed a correlation between LUM-201's pulsatile mechanism of action and growth, with increases in IGF-1 and IGFBP-3 levels. - Lumos Pharma plans to advance oral LUM-201 into a Phase 3 clinical trial for moderate PGHD next year.
- Lumos Pharma's LUM-201 met all primary and secondary endpoints in Phase 2 clinical trials, indicating its potential in treating pediatric growth hormone deficiency. - The oral growth hormone secretagogue, LUM-201, uniquely stimulates growth hormone release with a pulsatile mechanism, demonstrating durable results up to 24 months. - Analysts are optimistic about Lumos Pharma's financial stability, with sufficient funds to support operations into Q1 2025 and potential Phase 3 trials.
